Stock Price
2.33
Daily Change
-0.04 -1.69%
Monthly
-20.48%
Yearly
76.52%
Q2 Forecast
2.28

Galectin Therapeutics reported $71.74M in Debt for its fiscal quarter ending in December of 2023.





Debt Change Date
AbbVie USD 1000K 70.48B Sep/2025
Bristol-Myers Squibb USD 51.04B 112M Sep/2025
Galectin Therapeutics USD 71.74M 10.6M Dec/2023
Gilead Sciences USD 24.94B 5M Dec/2025
Immunic USD 0 0 Jun/2024
Incyte USD 40.41M 855K Dec/2025
Merck USD 41.37B 5.97B Sep/2025